Affiliation:
1. National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, University of Science and Technology
2. Southern Medical University
Abstract
Abstract
Monkeypox cases continue to increase globally, and there is an urgent need to develop a highly effective vaccine against monkeypox. This study investigated the binding and authentic-virus neutralizing activities of sera from mice immunized with EEV (extracellularly enveloped viruses) antigens B6R and A35R, and IMV (intrinsic material viruses) antigens M1R, A29L, E8L, and H3L against monkeypox virus. The results showed that immunizations of A35R and E8L could only induce lower titers of binding antibodies, in contrast, immunization of M1R induced the highest titers of binding antibodies, while immunization of B6R, H3L, and A29L induced moderate titers of binding antibodies. For the live monkeypox virus neutralization assay, the results showed that immunization with two doses of EEV antigen B6R did not effectively induce humoral immune responses to neutralize monkeypox live virus, immunization with EEV-A35R only induced weak monkeypox-neutralizing antibodies. In contrast, the immunization of the four types of monkeypox virus IMV antigens can all induce neutralizing antibodies against authentic monkeypox virus, among them, A29L and H3L induced the highest neutralizing antibody titers. The results of this study provide important references for the selection of antigens in the development of the next generation of monkeypox vaccines.
Publisher
Research Square Platform LLC
Reference13 articles.
1. Monkeypox: disease epidemiology, host immunity and clinical interventions;Lum F-M;Nat Rev Immunol,2022
2. Rising prevalence of mpox in China, Japan, and Republic of Korea;Xu T;J Infect,2023
3. Antibody Titers against Mpox Virus after Vaccination;Kottkamp AC;N Engl J Med,2023
4. A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination;Bottanelli M;Lancet Infect Dis,2024
5. Mahase E, Monkeypox. Single dose of smallpox vaccine offers 78% protection, UKHSA reports. BMJ 379, o2829, 10.1136/bmj.o2829 (2022).